ArticleBritish journal of cancer2024

KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma.

Jan Budczies et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.